Table 2.

Summary of changes in VH:CrD values within study time points according to HLA-DQ2/HLA-DQ8 genotype groups

Group	n	GFD mean ± s.d.	PGC mean ± s.d.	Change in ratio from GFD (95% CI)	P value
Drug
G1	6	2.08 ± 0.5	1.54 ± 0.23	−0.54 (−1.07 to −0.01)	0.05
G2	14	2.05 ± 0.27	1.84 ± 0.46	−0.21 (−0.43 to 0.02)	0.07
G3	14	2.17 ± 0.33	2.1 ± 0.27	−0.08 (−0.27 to 0.11)	0.39
Interaction term time point: HLA-DQ genetic group				0.06*
Placebo
G1	2	2.23 ± 0.25	0.54 ± 0.15	−1.69 (−2.65 to −0.74)	0.03
G2	6	1.77 ± 0.38	1.09 ± 0.56	−0.69 (−1.23 to −0.15)	0.02
G3	15	2.00 ± 0.35	1.63 ± 0.57	−0.38 (−0.62 to −0.13)	0.005
Interaction term time point: HLA-DQ genetic group				0.003*

Values are shown as mean ± s.d. The change from GFD is presented as a least-squares means estimate. P values for interactions are marked with an asterisk (*) and were calculated as part of a repeated-measures ANOVA; other P values were obtained from pairwise comparisons using two-tailed t-tests.